Abstract 862: Sensitization of pancreatic cancer to chemoradiation by the Wee1 inhibitor AZD1775

@article{Kausar2014Abstract8S,
  title={Abstract 862: Sensitization of pancreatic cancer to chemoradiation by the Wee1 inhibitor AZD1775},
  author={T. Kausar and L. A. Parsels and J. Parsels and D. Karnak and Mary A Davis and J. Maybaum and T. Lawrence and M. Morgan},
  journal={Cancer Research},
  year={2014},
  volume={74},
  pages={862-862}
}
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Gemcitabine-based chemoradiation is standard therapy for locally advanced pancreatic cancer and is associated with an approximately one year median survival. In order to improve the efficacy of this therapy, integration of agents which target the DNA damage response, such as inhibitors of Wee1, is a promising strategy. The goals of this study were to determine the efficacy of the Wee1 inhibitor AZD1775 in sensitizing… Expand
2 Citations
Targeting Mcl-1 for Radiosensitization of Pancreatic Cancers12
Integrating chemoradiation and molecularly targeted therapy☆